Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High transferrin saturation predicts inferior clinical outcomes in patients with myelodysplastic syndromes.
Teichman J, Geddes M, Zhu N, Keating MM, Sabloff M, Christou G, Leber B, Khalaf D, St-Hilaire E, Finn N, Shamy A, Yee KWL, Storring JM, Nevill TJ, Delage R, Elemary M, Banerji V, Houston B, Mozessohn L, Chodirker L, Zhang L, Siddiqui M, Parmentier A, Leitch HA, Buckstein RJ. Teichman J, et al. Among authors: delage r. Haematologica. 2023 Feb 1;108(2):532-542. doi: 10.3324/haematol.2022.280723. Haematologica. 2023. PMID: 35979720 Free PMC article.
An MDS-specific frailty index based on cumulative deficits adds independent prognostic information to clinical prognostic scoring.
Starkman R, Alibhai S, Wells RA, Geddes M, Zhu N, Keating MM, Leber B, Chodirker L, Sabloff M, Christou G, Leitch HA, St-Hilaire E, Finn N, Shamy A, Yee K, Storring J, Nevill T, Delage R, Elemary M, Banerji V, Lenis M, Kirubananthaan A, Mamedov A, Zhang L, Rockwood K, Buckstein R. Starkman R, et al. Among authors: delage r. Leukemia. 2020 May;34(5):1394-1406. doi: 10.1038/s41375-019-0666-7. Epub 2019 Dec 6. Leukemia. 2020. PMID: 31811236
Patient-reported fatigue refines prognosis in higher-risk myelodysplastic syndromes (MDS): a MDS-CAN study.
Amitai I, Geddes M, Zhu N, Keating MM, Sabloff M, Christou G, Leber B, Khalaf D, Leitch HA, St-Hilaire E, Finn N, Shamy A, Yee K, Storring J, Nevill T, Delage R, Elemary M, Banerji V, Chodirker L, Mozessohn L, Parmentier A, Siddiqui M, Mamedov A, Zhang L, Buckstein R. Amitai I, et al. Among authors: delage r. Br J Haematol. 2021 Jul;194(2):319-324. doi: 10.1111/bjh.17537. Epub 2021 May 31. Br J Haematol. 2021. PMID: 34060069
A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry.
Buckstein R, Chodirker L, Mozessohn L, Yee KWL, Geddes M, Zhu N, Shamy A, Leitch HA, Christou G, Banerji V, Brian L, Khalaf D, St-Hilaire E, Finn N, Nevill T, Keating MM, Storring J, Delage R, Parmentier A, Thambipillai A, Siddiqui M, Westcott C, Cameron C, Mamedov A, Spin P, Tang D. Buckstein R, et al. Among authors: delage r. Leuk Lymphoma. 2022 Dec;63(13):3165-3174. doi: 10.1080/10428194.2022.2109154. Epub 2022 Sep 12. Leuk Lymphoma. 2022. PMID: 36095125
Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.
Leitch HA, Parmar A, Wells RA, Chodirker L, Zhu N, Nevill TJ, Yee KWL, Leber B, Keating MM, Sabloff M, St Hilaire E, Kumar R, Delage R, Geddes M, Storring JM, Kew A, Shamy A, Elemary M, Lenis M, Mamedov A, Ivo J, Francis J, Zhang L, Buckstein R. Leitch HA, et al. Among authors: delage r. Br J Haematol. 2017 Oct;179(1):83-97. doi: 10.1111/bjh.14825. Epub 2017 Jul 5. Br J Haematol. 2017. PMID: 28677895 Free article.
A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registry.
Houston BL, Jayakar J, Wells RA, Lenis M, Zhang L, Zhu N, Leitch HA, Nevill TJ, Yee KWL, Leber B, Sabloff M, St-Hilaire E, Kumar R, Geddes M, Shamy A, Storring JM, Keating MM, Elemary M, Delage R, Mamedov A, Buckstein R. Houston BL, et al. Among authors: delage r. Ann Hematol. 2017 Dec;96(12):2025-2029. doi: 10.1007/s00277-017-3137-0. Epub 2017 Oct 3. Ann Hematol. 2017. PMID: 28975386
Revised 15-item MDS-specific frailty scale maintains prognostic potential.
Wan BA, Nazha A, Starkman R, Alibhai S, Wells RA, Geddes M, Zhu N, Keating MM, Leber B, Chodirker L, Sabloff M, Christou G, Leitch HA, St-Hilaire E, Finn N, Shamy A, Yee KWL, Storring J, Nevill TJ, Delage R, Elemary M, Banerji V, Parmentier A, Siddiqui M, Kirubananthaan A, Mamedov A, Zhang L, Buckstein R. Wan BA, et al. Among authors: delage r. Leukemia. 2020 Dec;34(12):3434-3438. doi: 10.1038/s41375-020-01026-y. Epub 2020 Aug 28. Leukemia. 2020. PMID: 32855438 No abstract available.
BCR-ABL1 transcript doubling time as a predictor for treatment-free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase.
Kim DDH, Kim TS, Atenafu EG, Novitzky Basso I, Forrest D, Bence-Bruckler I, Savoie L, Busque L, Keating MM, Delage R, Xenocostas A, Liew E, Paulson K, Stockley T, Laneuville P, Lipton JH, Kamel-Reid S, Leber B. Kim DDH, et al. Among authors: delage r. Br J Haematol. 2022 Jan;196(1):136-145. doi: 10.1111/bjh.17807. Epub 2021 Sep 8. Br J Haematol. 2022. PMID: 34496035
Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial.
Kim DDH, Novitzky-Basso I, Kim TS, Atenafu EG, Forrest D, Savoie L, Bence-Bruckler I, Keating MM, Busque L, Delage R, Xenocostas A, Liew E, Paulson K, Stockley T, Laneuville P, Lipton JH, Kamel-Reid S, Leber B. Kim DDH, et al. Among authors: delage r. Br J Haematol. 2021 May;193(4):779-791. doi: 10.1111/bjh.17447. Epub 2021 Apr 20. Br J Haematol. 2021. PMID: 33876423 Clinical Trial.
67 results